Susy M. Scholl, Maud Kamal, Leanne De Koning, Attila Kereszt, Ekaterina S. Jordanova, Sergiu Ungureanu, Els Berns and Xavier Sastre Pages 1379 - 1394 ( 16 )
Cervical cancer is the second most common malignancy among women worldwide. While more than 90% of cervical cancers carry one or more high risk HPV types, the exact relationship between HPV oncoproteins and signaling pathways alterations in cervical cancer remains to be clarified. Vaccines and targeted therapies are today considered of great potential for the improvement of patients’ outcome. This review will focus on the interaction of HPV with cervical cancer pathway activations. Next generation high throughput screening technologies for molecular and protein profiling as well as innovative logistics, necessary for the implementation of the personalized care of cervical cancer patients will be discussed.
Cervical cancer, HPV, vaccines, omics, targeted therapy, malignancy, oncoproteins, signaling pathways, protein profiling, personalized care
, , , , , , , Medecin Specialiste, Departement d'Oncologie, Institut Curie, Paris, France.